The Phage Futures Congress will bring together peers from biotech companies and academia, along with experts from regulatory bodies, pharmaceutical companies and government institutions, to discuss how to actively progress clinical science and viable phage application routes to market. You will hear about:Regulatory guidance to achieve clinical data from Cara Fiore, FDAStrategies to access the market via the veterinary, personalized medicine and traditional pharmaceutical routesInsights into investment drivers for phage therapy from NIH and Boehringer IngelheimFacts on how to manufacture GMP phageApplications to overcome multi-drug resistance with combined approaches such as phage therapy and antibiotics "This congress has the potential to act as a catalyst to further cooperative and collaborative efforts to develop alternate Phage based approaches to the antibiotic crisis. In addition, the location in the Washington DC area will facilitate an opportunity for Government Agencies, responsible for public health, such as the NIH, FDA, USDA and DOD to participate and interact with educational research groups and biotechnology companies developing phage therapies and initiating clinical testing." - Carl Merril, Adaptive Phage Therapeutics